FDA fast-tracks EO2463 immunotherapy for follicular lymphoma, promising a new treatment option backed by positive trial data ...
A study published in Cancer Discovery finds that combining an epigenetic therapy with an anti-PD-1 antibody, which uses the ...
News Medical on MSN
New combination therapy shows promise for aggressive lymphoma resistant to immunotherapy
Combining an epigenetic therapy with an anti-PD-1 antibody, which uses the body’s natural response to viral infections, showed promising results in patients with relapsed or refractory natural ...
At Ochsner Cancer Center of Acadiana, people diagnosed with blood cancers find more than the latest treatments — they also ...
Discover innovative immunotherapy strategies that leverage the immune system to combat hematological malignancies effectively ...
Enterome has received fast track designation from the US Food and Drug Administration for its lead OncoMimics immunotherapy EO2463, targeting follicular lymphoma in the low tumour burden ...
The FDA has approved the combination of lurbinectedin (Zepzelca) and the immunotherapy atezolizumab (Tecentriq) for first-line maintenance treatment in patients with extensive-stage small cell lung ...
Cancer is classified as the uncontrollable growth of mutated cells. There are different types of cancers that correlate to ...
The event will provide clinical perspectives and market outlook for lacutamab, Innate’s lead proprietary product progressing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback